Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 12/20 | 0.42 |
| ▸ | ACACA | Q13085 | 7/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24631462 | 1.00 | ACACB (0.42) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL30134797 | 1.00 | ACACB (0.42) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL24631825 | 0.90 | ACACB (0.43) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL30134736 | 0.90 | ACACB (0.43) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL24631455 | 0.90 | ACACB (0.43) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL30134766 | 0.86 | ACACB (0.41) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL30134764 | 0.86 | ACACB (0.41) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL24631674 | 0.86 | ACACB (0.41) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL24631670 | 0.86 | ACACB (0.41) | ACACBACACADRD2CKS1BSKP1 | |
| SCHEMBL30031182 | 0.80 | ACACB (0.40) | ACACBACACADRD2CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022217265-A1 | TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |